论文部分内容阅读
目的：观察重组人生长激素（r-hGH）治疗肝硬化低蛋白血症的疗效。方法：肝硬化病人21例，Child分级A级3例、B级13例、C级5例，所有患者无合并肝癌及糖尿病。予r-hGH 4 IU，皮下注射，第一周及第二周隔日1次，第三、四周每周2次，4周为1疗程。疗程结束后观察治疗前、后血清前清蛋白、清蛋白、血糖、ALT及胆红素的变化。结果：血清前清蛋白治疗前（279±26）mg／L，治疗后（436±57）mg／L，P ＜0．05；清蛋白治疗前（29±3）g／L，治疗后（34±4）g／L，P ＜0．05；空腹血糖治疗前（4．2±0．6）mmol／L，治疗后（4．9±0．7）mmol／L，P ＞0．05；ALT及血清胆红素治疗前后均无明显变化。结论：r-hGH能提高肝硬化低蛋白血症患者血清前清蛋白及清蛋白水平，尤其对Child A级和B级患者尤为明显。
Objective: To observe the effect of recombinant human growth hormone (r-hGH) on cirrhosis and hypoproteinemia. Methods: Twenty-one patients with cirrhosis, 3 patients were classified as Child Grade A, 13 patients were Grade B, 5 patients were Grade C, all patients had no hepatocellular carcinoma and diabetes mellitus. To r-hGH 4 IU, subcutaneous injection, the first week and the second week after every other day, the third, four weeks twice a week, 4 weeks for a course of treatment. After treatment, the changes of serum prealbumin, albumin, blood glucose, ALT and bilirubin were observed before and after treatment. Results: Serum prealbumin was (279 ± 26) mg / L before treatment (436 ± 57) mg / L, P <0.05; before albumin treatment was (29 ± 3) g / 34 ± 4) g / L, P <0.05; fasting blood glucose before treatment was (4.2 ± 0.6) mmol / L and after treatment was (4.9 ± 0.7) mmol / L, P> 05; ALT and serum bilirubin no significant changes before and after treatment. Conclusion: r-hGH can improve serum albumin and albumin levels in patients with cirrhosis and hypoproteinemia, especially in Child A and B patients.